CSL (OTCMKTS:CSLLY) Raised to “Hold” at Zacks Research

CSL (OTCMKTS:CSLLY) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Separately, Canaccord Genuity Group raised CSL from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, CSL presently has a consensus rating of “Buy”.

CSL Stock Performance

Shares of CSLLY opened at $57.99 on Monday. CSL has a 1-year low of $54.10 and a 1-year high of $90.04. The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50. The firm’s 50-day moving average price is $59.79 and its 200-day moving average price is $70.09.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.